Two clusters of unknown illness kill over 50 in Democratic Republic of Congo
LONDON, Feb 25 (Reuters) - More than 50 people have died in recent weeks in two clusters of illness cases with unknown cause being investigated in northwest Democratic Republic of Congo, the World Health Organization said on Tuesday.
As of February 16, there have been 431 cases and 53 deaths in two outbreaks in remote villages in separate health zones in Equateur province, the WHO said in a bulletin. The country is roughly the size of Western Europe.
"The outbreaks, which have seen cases rise rapidly within days, pose a significant public health threat. The exact cause remains unknown," WHO spokesperson Tarik Jasarevic told a briefing on Tuesday.
The villages have limited surveillance capacity and health infrastructure, he noted.
The larger outbreak, reported on 13 February from Bomate village in Equateur's Basankusu health zone, has killed 45 people out of 419 cases. Almost half died within 48 hours of falling ill, the WHO said, with symptoms including fever, pain, vomiting and diarrhoea.
Samples from 13 cases have tested negative for Ebola and Marburg, but the WHO said health teams were locally investigating other potential causes, including malaria, food poisoning, typhoid, meningitis or other viral haemorrhagic fever.
An earlier outbreak, involving eight deaths among 12 cases, was reported from Boloko Village in Bolomba health zone on January 21, WHO said.
This outbreak was traced back to three deaths among children under five years old in the village earlier that month. Symptoms including fever and fatigue progressed to haemorrhagic signs such as nosebleeds and vomiting blood.
Reports indicated that the children had eaten a dead bat before falling ill.
The other cases were found in the same village and nearby Dondo village, all with similar symptoms. At the end of January, samples taken from patients all tested negative for Ebola and Marburg.
The WHO said no links have been established between the two clusters of cases.
"We are looking into whether it is another infection or whether it is some toxic agent. We have to see what can be done and at what point WHO can support," said Jasarevic, noting similar outbreaks in the past.
An outbreak of unknown cause reported in Congo in December was ultimately identified as malaria.
This article originally appeared on USA TODAY: Democratic Republic of Congo: Two clusters of unknown illness kill over 50

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
US FDA approves Merck's RSV antibody for infants
(Reuters) -The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year of age from respiratory syncytial virus during their first RSV season, the company said. The United States has seen limited supply of Sanofi and AstraZeneca's antibody Beyfortus, the only preventive shot for RSV available in the country for infants and toddlers so far. Merck's therapy, called clesrovimab and branded as Enflonsia, is a monoclonal antibody that can be administered as a single dose regardless of birth weight in healthy pre-term, full-term and at-risk infants to protect them against mild, moderate and severe RSV. RSV is a common respiratory virus that causes seasonal infections such as the flu, but is a leading cause of pneumonia and death in infants and older adults. The approval was based on results from a late-stage trial in which Enflonsia had a comparable safety profile to Swedish Orphan Biovitrum's Synagis, a monthly injection. Merck said that Enflonsia is the first and only RSV preventive option administered to infants using the same dose regardless of weight, and it told Reuters the drug will be priced at $556 per dose. Jefferies analyst Akash Tewari said last year that this is beneficial since physicians have to forecast an infant's potential weight during RSV season with Beyfortus, which makes dose ordering and inventory more complex. In the U.S., an estimated 58,000–80,000 children younger than five years are hospitalized due to RSV each year, according to the U.S. Centers for Disease Control and Prevention. The CDC currently recommends two immunization options for babies to be protected from severe RSV — an RSV vaccine given to the mother during pregnancy or an RSV antibody given to the baby. Merck expects the drug's shipments to arrive in time for the 2025-2026 RSV season. The CDC's Advisory Committee on Immunization Practices is expected to meet later this month to discuss and make recommendations for the use of Enflonsia in infants.
Yahoo
an hour ago
- Yahoo
US FDA approves Merck's RSV antibody for infants
(Reuters) -The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year of age from respiratory syncytial virus during their first RSV season, the company said. The United States has seen limited supply of Sanofi and AstraZeneca's antibody Beyfortus, the only preventive shot for RSV available for infants and toddlers so far. Merck's therapy, called clesrovimab and branded as Enflonsia, is a monoclonal antibody that can be administered as a single dose regardless of birth weight in healthy pre-term, full-term and at-risk infants to protect them against mild, moderate and severe RSV. RSV is a common respiratory virus that causes seasonal infections such as the flu, but is a leading cause of pneumonia and death in infants and older adults. Each year in the United States, an estimated 58,000–80,000 children younger than five years are hospitalized due to RSV, according to the U.S. Centers for Disease Control and Prevention. The CDC currently recommends two immunization options for babies to be protected from severe RSV — an RSV vaccine given to the mother during pregnancy or an RSV antibody given to the baby. Merck expects the drug's shipments to arrive in time for the 2025-2026 RSV season. The CDC's Advisory Committee on Immunization Practices is expected to meet later this month to discuss and make recommendations for the use of Enflonsia in infants.
Yahoo
6 hours ago
- Yahoo
UK's MHRA suspends Valneva's chikungunya vaccine for elderly
(Reuters) -UK's medicine regulator said on Monday it has temporarily restricted the use of French vaccine maker Valneva's shot to treat chikungunya, a virus transmitted by mosquitoes, in people aged 65 and above as a precautionary measure. The vaccine, IXCHIQ, was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in February to protect people aged 18 years and above against chikungunya, but is not yet available in the UK market. "The decision to restrict the licence until further review is based on global data which has highlighted 23 cases of serious adverse reactions, including two cases reporting a fatal outcome, in people aged from 62 to 89 years of age who received the vaccine," the regulator said. The adverse events were reported in the French overseas territory of La Reunion, where a chikungunya outbreak was reported earlier this year. MHRA's decision comes after the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) in May suspended the use of the vaccine in the age group. The French Government was the first to take the step in April.